Balaji Amines Q1: margin recovery more than doubles consolidated PAT to ₹78 Cr

Balaji Amines opened FY27 with a sharp profitability recovery. Consolidated revenue rose 27.2% YoY to ₹455.9 Cr (+15.5% QoQ) while profit for the period more than doubled to ₹78.1 Cr, up 113.9% YoY and 20.6% sequentially — the print the company flagged in its 27 July release as an ~81% jump, which refers to the standalone base (standalone PAT ₹72.1 Cr, +81.3% YoY). The gap between the two bases is itself the news: the consolidated line grew faster because subsidiary Balaji Speciality Chemicals swung back, with minority interest turning from −₹1.5 Cr a year ago to +₹3.2 Cr this quarter.

The engine was margin, not just volume. Operating margin rebounded to roughly 25.4% from 15.3% in the year-ago quarter, as cost of materials consumed fell as a share of revenue versus Q1 FY26 — the amines & specialty chemicals segment delivered ₹105.4 Cr of pre-interest profit on ₹452.9 Cr of segment revenue, against just ₹45.4 Cr a year earlier. The small hotel division was steady-to-softer (segment profit ₹1.5 Cr vs ₹3.8 Cr). Other income was modest at ₹5.5 Cr and there were no exceptional items on either side, so the growth is clean and underlying — no adjustment needed.

The stock went into the print at ₹2,284.8, up 14.9% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

No exceptional items — growth is clean/underlying; results limited-reviewed, unmodified opinion

Against management's own FY27 framing from the Q4 concall — 10-15% volume growth and a stable 22-23% EBITDA band — this quarter runs ahead on both counts: revenue growth is well above the volume guide and the operating margin sits above the guided band, consistent with the June clarification that the recent volume surge is market-driven. The result validates the confident tone management carried into FY27 and keeps the ₹3,000 Cr-by-FY28 revenue ambition (and the Balaji Speciality Chemicals ₹750 Cr expansion) on the table. No brokerage consensus for this mid-cap was locatable, so the print is judged against the company's own guidance rather than a street number. Board also set a ₹11 final dividend (3 July record date) alongside the quarter.